Search
EHA supports the European Medicines Agency's investigation into risk based quality management of clinical trials
EHA has responded to the EMA’s call for comments on the reflection paper on February 15.
Read moreTarget audience
You are a hematologist working at an academic center or a large community hospital that is known for running clinical trials.
Read moreEHA-EMN Joint Session at the European Myeloma Network Meeting EMN2023
On Saturday, 22 April, EHA and EMN brought together patients, regulators and clinicians to discuss Novel Endpoints in Multiple Myeloma.
Read moreGenetic Predisposition to Blood Cancer (Rare diseases)
The objectives of the group are:
Share and extend clinical knowledge on the diagnosis and treatment of hematologic malignancies with germline predisposition.